Quarterly report [Sections 13 or 15(d)]

Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.26.3
Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Segment Information    
Number of reportable segment not disclosed true  
Revenues, net $ 299,712 $ 286,555
Consolidated net sales 299,712 286,555
Cost of sales 103,089 98,443
Selling, general and administrative 133,679 116,213
Research and development 26,341 24,241
Operating income 36,603 47,658
Recovery of assets held-for-sale   6,789
Consumables    
Segment Information    
Revenues, net 237,257 231,601
Operating Segments    
Segment Information    
Revenues, net 299,855 281,646
Operating income 89,095 86,591
Operating Segments | Protein Sciences    
Segment Information    
Revenues, net 219,691 202,188
Cost of sales 57,592 50,518
Selling, general and administrative 63,001 59,766
Research and development 15,900 14,191
Operating income 83,198 77,713
Operating Segments | Diagnostics and Spatial Biology    
Segment Information    
Revenues, net 80,164 79,458
Cost of sales 34,503 33,737
Selling, general and administrative 29,317 27,851
Research and development 10,447 8,992
Operating income 5,897 8,878
Operating Segments | Other revenue    
Segment Information    
Other revenues   5,439
Intersegment Eliminations    
Segment Information    
Revenues, net (143) (530)
Corporate, Non-Segment    
Segment Information    
Selling, general and administrative 1,428 2,433
Amortization of intangibles (14,663) (15,350)
Acquisition related expenses and other (17,760) (3,351)
Certain litigation charges (46) (2,408)
Stock based compensation, inclusive of employer taxes (14,757) (12,096)
Restructuring and restructuring-related costs $ (3,838) (7,511)
Impact of business held-for-sale(1)   $ (2,573)